Consensus Azenta, Inc.

Stocks

AZTA

US1143401024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 19/06/2026 +04			5-day change	1st Jan Change
23.31 ^USD	+2.80%		+3.19%	-29.92%

05-07	Needham Cuts Price Target on Azenta to $33 From $44, Keeps Buy Rating	MT
05-06	Azenta, Inc., Q2 2026 Earnings Call, May 06, 2026

Evolution of the Average Target: Azenta, Inc.

Evolution of the Target Price: Azenta, Inc.

Changes in Analyst Recommendations: Azenta, Inc.

59bf.w6YgxlgrHMOfPWY2opNMdaU-q-tqA4H5mcgbpW2Y0GA.9-N_tT4acq_Wf1Fg8qV4OM9n4IAIduWf__B16CfdhFWoy3WsDWFG-tpPCQ~48bb7a3f5c58bf84eb913fb49121e460

Analysts' recommendations: Azenta, Inc.

05-07	Needham Cuts Price Target on Azenta to $33 From $44, Keeps Buy Rating	MT
12-19	Needham Raises Price Target on Azenta to $44 From $42, Keeps Buy Rating	MT
11-24	Needham Raises Price Target on Azenta to $42 From $40, Keeps Buy Rating	MT
30/10/25	Jefferies Upgrades Azenta to Buy From Hold, Adjusts Price Target to $38 From $30	MT
06/08/25	Raymond James Upgrades Azenta to Outperform From Market Perform	MT
07/05/25	Needham Adjusts Price Target on Azenta to $40 From $59, Keeps Buy Rating	MT
27/02/25	TD Cowen Initiates Coverage on Azenta With Hold Rating, $50 Price Target	MT
18/12/24	Stephens Upgrades Azenta to Overweight From Equal Weight, Adjusts Price Target to $60 From $50	MT
09/05/24	Needham Adjusts Price Target on Azenta to $69 From $75, Keeps Buy Rating	MT
04/04/24	Evercore ISI Raises Azenta's Price Target to $60 From $64, Maintains In Line Rating	MT
04/04/24	Jefferies Initiates Coverage on Azenta With Hold Rating, $64 Price Target	MT
08/02/24	Needham Trims Price Target on Azenta to $75 From $76, Maintains Buy Rating	MT
01/02/24	B. Riley Adjusts Azenta's Price Target to $79 From $61 Ahead of Fiscal Q1 Results Announcement, Keeps Buy Rating	MT
18/01/24	Needham Adjusts Azenta's Price Target to $76 From $68, Keeps Buy Rating	MT
09/08/23	Needham Raises Price Target on Azenta to $65 From $55, Maintains Buy Rating	MT
04/08/23	B. Riley Lowers Azenta's PT to $61 From $68 After Lower-Than-Consensus Fiscal Q3 Revenue, Keeps Buy Rating	MT
19/07/23	Raymond James Initiates Azenta With Market Perform Rating	MT
10/05/23	Needham Adjusts Price Target on Azenta to $55 From $68, Keeps Buy Rating	MT
10/05/23	KeyBanc Downgrades Azenta to Sector Weight From Overweight After Fiscal Q2 Miss, Says B-Medical 'Reduces Visibility'	MT
10/02/23	B. Riley Lowers Azenta's Price Target to $68 From $77, Keeps Buy Rating	MT
09/02/23	Needham Adjusts Price Target on Azenta to $68 From $78, Maintains Buy Rating	MT
09/02/23	Stephens Downgrades Azenta to Equalweight From Overweight, Adjusts Price Target to $60 From $65	MT
08/02/23	Needham Raises Price Target for Azenta to $78 From $74, Maintains Buy Rating	MT
03/01/23	Evercore ISI Downgrades Azenta to In Line From Outperform, Adjusts Price Target to $62 From $60	MT
15/11/22	Needham Raises Price Target on Azenta to $78 From $74, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AZENTA, INC.					+12.4%
	LONZA GROUP AG					+33.05%
	REVOLUTION MEDICINES, INC.					+14.91%
	BEONE MEDICINES AG					+52.64%
	IQVIA HOLDINGS INC.					+34.39%
	CELLTRION, INC.					+49.16%
	MEDPACE HOLDINGS, INC.					-3.63%
	EUROFINS SCIENTIFIC SE					+13.38%
	IONIS PHARMACEUTICALS, INC.					+41.54%
	Average					+27.54%
	Weighted average by Cap.					+31.77%